太龙药业：拟向特定对象增发募资不超过约4.54亿元

Group 1 - The core point of the article is that Tailong Pharmaceutical has approved a private placement of A-shares to Jiangyao Holdings, aiming to raise approximately 454 million yuan for working capital and debt repayment [1] - The number of shares to be issued is not more than approximately 74.61 million, accounting for 13% of the company's total share capital before the issuance [1] - The issuance price is set at 6.09 yuan per share, and the final number of shares will be determined in accordance with regulations and discussions with the underwriter [1] Group 2 - For the first half of 2025, Tailong Pharmaceutical's revenue composition is as follows: 70.59% from pharmaceutical manufacturing, 14.71% from pharmaceutical research and development, 14.42% from pharmaceutical distribution, and 0.28% from other businesses [1] - As of the report date, Tailong Pharmaceutical has a market capitalization of 4.9 billion yuan [1]